Ricursive Intelligence, founded by two former Google researchers and valued at $4 billion, is among several efforts to automate the creation of artificial intelligence. Anna Goldie and Azalia ...

Let’s be real: Running 26.2 miles isn’t easy. Even if it feels like everyone around you is training to run a marathon these days, less than 1 percent of the population actually conquers the iconic ...

Welcome to Stationery Week on the Strategist, where we’ve been obsessively researching and testing office supplies — everything from pens, pencils, and paper to task chairs. For more, head to our ...

Recursion Pharmaceuticals' AI-based approach has the potential to transform the pharmaceutical industry. However, it is still chasing clinical wins that would demonstrate the power of its strategy.

JDK 25 brings powerful new features to Java and JVM developers. Here are seven new or updated features that could convince you to switch. Java continues its fast and feature-packed release schedule, ...

Amidst the AI boom transforming various sectors, Recursion Pharmaceuticals (NASDAQ: RXRX), a previously beaten-down AI-biotech, is showing signs of a rebound. Its stock has skyrocketed 25% in the past ...

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) stock is surging on Wednesday, without any news to justify the movement. Session volume stands at 69.3 million versus the average volume of 26.9 million, ...

Sept 2 (Reuters) - Drug developers are increasing adoption of AI technologies for discovery and safety testing to get faster and cheaper results, in line with an FDA push to reduce animal testing in ...